Pfizer Vaccines (Photo: Geovana Albuquerque / Agência Saúde DF)
The Pfizer This Friday (19) sent to the National Health Surveillance Agency (Anvisa), a request for the emergency use of a new vaccine against covid-19. The novelty of immunization with respect to others already given in Brazil is that it is of the bivalent type and is able to protect people from the micron strain, for which there is no coverage yet and which caused the outbreak at the beginning of the year.
The response to the request must be announced within 30 days.
According to the agency, Pfizer intends to use the bivalent vaccine, which is made from parts of the original strain of the novel coronavirus and parts of a surrogate micron, as a booster dose for people over 12 years old.
Last Monday, the 15th, the UK became the first country in the world to approve the use of a bivalent vaccine against Covid-19. The approved ban is made by Moderna. The information has been released by the Medicines and Health Products Regulatory Agency (MHRA). Through a statement, Anvisa informed that Pfizer representatives met with members of the regulatory agency to introduce the new vaccine prior to submitting an emergency use request.
The company’s vaccinations have been applied to the Brazilian population since February last year, and are currently given to people over the age of 5. Currently, Pfizer is awaiting another license application to Anvisa to use the vaccine in children older than six months. The application was submitted on August 1, and the agency has yet to announce its decision.
To date, Brazil has vaccinated 180.4 million people against COVID-19 with at least one dose of the vaccine (equivalent to 84% of the population); 169.7 million with two doses (79%) and 101.5 million with the third dose.
According to data from the Press Federation, of which Estadão is a part, and compiled with state health secretariats, the country records a total of 682,457 deaths from the novel coronavirus and more than 34.2 million infections caused by the virus. the onset of the pandemic.
